News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Medicine Facility Ushers in a New Era of Immune Health Discovery
The new facility will serve as an interdisciplinary research hub.
Penn Develops a New Supercomputer to Run Large AI models
Betty is Penn's new supercomputer.
Penn’s Carter Caldwell Weighs in On Pre-Launch Business Validation
Caldwell addresses the importance of customer discovery and shares online resources.
PCI’s Ben Dibling Provides Insight on Commercialization Strategies
Dibling explains different commercialization scenarios recommended to faculty.
Carl June Speaks to the Inquirer About the Future of CAR-T Therapy
June explains the applications of CAR-T applications beyond blood cancers.
Future mRNA Vaccines May Prevent Food and Seasonal Allergies
These advancements are paving the way for potential future treatments for seasonal and food allergies in humans.
I-Corps Graduate Serpent Robotics Wins the Eighth Annual Pennovation Accelerator Pitch Day
Serpent is formed around robotic arm technology invented by Mark Yim, PhD.
Regenxbio Showcases Promising Gene Therapy Data for Hunter Syndrome Treatment
The company reported long-term data demonstrating that its experimental treatment for Hunter syndrome, a rare genetic disorder.
GEMMABio Launches Rare Therapeutics. to Develop and Deliver Gene Therapies for Rare Diseases
Rare Therapeutics is a clinical-stage company focused on developing accessible and sustainable gene therapies for ultra-orphan diseases.
MavriX Bio Receives FDA Fast Track Designation for Angelman Syndrome Treatment
MavriX is a Penn startup company based on technology developed by James Wilson, MD, PhD.